Advanced

Novel strategies for the treatment of grass pollen-induced allergic rhinitis

Larsson, Olivia; Hellkvist, Laila; Peterson-Westin, Ulla LU and Cardell, Lars Olaf LU (2016) In Expert Opinion on Biological Therapy 16(9). p.1143-1150
Abstract

Introduction: Allergic rhinitis (AR) affects over 20% of the population of Europe and the United States. Allergen immunotherapy (AIT) is currently the only form of treatment that affects symptoms and modifies the progression of disease. Established forms of AIT include subcutaneous (SCIT) and sublingual (SLIT) immunotherapy and are widely effective, yet only 2-9% of eligible patients undergo therapy, likely due to the long duration of treatment. As a result, novel, faster forms of AIT are currently under development. Areas covered: This article provides an overview of AR and summarises the efficacy and mechanisms of established forms of AIT, highlighting the current drawbacks. We discuss novel strategies of AIT that have been developed... (More)

Introduction: Allergic rhinitis (AR) affects over 20% of the population of Europe and the United States. Allergen immunotherapy (AIT) is currently the only form of treatment that affects symptoms and modifies the progression of disease. Established forms of AIT include subcutaneous (SCIT) and sublingual (SLIT) immunotherapy and are widely effective, yet only 2-9% of eligible patients undergo therapy, likely due to the long duration of treatment. As a result, novel, faster forms of AIT are currently under development. Areas covered: This article provides an overview of AR and summarises the efficacy and mechanisms of established forms of AIT, highlighting the current drawbacks. We discuss novel strategies of AIT that have been developed in an attempt to tackle these limitations, including epicutaneous, intradermal and intralymphatic immunotherapy (ILIT), focusing on ILIT, the treatment that has been most comprehensively assessed. Expert opinion: Current strategies to treat AR suffer from a poor safety profile and, importantly, lack of adherence. ILIT is a faster and safer form of AIT, with a treatment regime of only 12 weeks. Further validation is required, but ILIT, with its short and comparatively inexpensive protocol, has the potential to offer disease-modifying therapy to a larger number of patients.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
allergen immunotherapy, Allergic rhinitis, allergy, grass pollen, intralymphatic immunotherapy
in
Expert Opinion on Biological Therapy
volume
16
issue
9
pages
8 pages
publisher
Ashley Publications
external identifiers
  • scopus:84981743093
  • wos:000382346100008
ISSN
1471-2598
DOI
10.1080/14712598.2016.1190829
language
English
LU publication?
yes
id
5e525094-0a45-4e80-b99c-b2f0b8a3c734
date added to LUP
2016-11-11 15:50:05
date last changed
2017-09-18 11:30:02
@article{5e525094-0a45-4e80-b99c-b2f0b8a3c734,
  abstract     = {<p>Introduction: Allergic rhinitis (AR) affects over 20% of the population of Europe and the United States. Allergen immunotherapy (AIT) is currently the only form of treatment that affects symptoms and modifies the progression of disease. Established forms of AIT include subcutaneous (SCIT) and sublingual (SLIT) immunotherapy and are widely effective, yet only 2-9% of eligible patients undergo therapy, likely due to the long duration of treatment. As a result, novel, faster forms of AIT are currently under development. Areas covered: This article provides an overview of AR and summarises the efficacy and mechanisms of established forms of AIT, highlighting the current drawbacks. We discuss novel strategies of AIT that have been developed in an attempt to tackle these limitations, including epicutaneous, intradermal and intralymphatic immunotherapy (ILIT), focusing on ILIT, the treatment that has been most comprehensively assessed. Expert opinion: Current strategies to treat AR suffer from a poor safety profile and, importantly, lack of adherence. ILIT is a faster and safer form of AIT, with a treatment regime of only 12 weeks. Further validation is required, but ILIT, with its short and comparatively inexpensive protocol, has the potential to offer disease-modifying therapy to a larger number of patients.</p>},
  author       = {Larsson, Olivia and Hellkvist, Laila and Peterson-Westin, Ulla and Cardell, Lars Olaf},
  issn         = {1471-2598},
  keyword      = {allergen immunotherapy,Allergic rhinitis,allergy,grass pollen,intralymphatic immunotherapy},
  language     = {eng},
  month        = {09},
  number       = {9},
  pages        = {1143--1150},
  publisher    = {Ashley Publications},
  series       = {Expert Opinion on Biological Therapy},
  title        = {Novel strategies for the treatment of grass pollen-induced allergic rhinitis},
  url          = {http://dx.doi.org/10.1080/14712598.2016.1190829},
  volume       = {16},
  year         = {2016},
}